LONDON -- The parents of Charlie Gard, whose battle to get their critically ill baby experimental treatment stirred international sympathy and controversy, dropped their legal effort Monday, saying tearfully it was time to let their son die.
At an emotional court hearing, a lawyer for the baby's parents, Chris Gard and Connie Yates, said the couple was withdrawing a bid to have Charlie sent to the United States, where a doctor had offered to try to treat his rare genetic condition.
The decision came after new medical tests showed the 11-month-old, who has brain damage and cannot breathe unaided, had irreversible muscular damage.
Both parents wept in the packed courtroom at the High Court in London as lawyer Grant Armstrong made the announcement, his voice breaking.
"This case is now about time," Armstrong said. "Sadly, time has run out."
Outside court, Chris Gard said Charlie "won't make his first birthday in just under two weeks' time."
"We are about to do the hardest thing that we will ever have to do, which is to let our beautiful little Charlie go," he said.
Gard and Yates, who are in their 30s and from London, have fought for their son, who was born in August 2016 with mitochondrial depletion syndrome, a rare genetic disease.
The baby has been treated at Great Ormond Street Hospital in London, one of the world's leading children's hospitals. Doctors there say Charlie is in pain, and further treatment only would increase his suffering. They have sought permission from the courts to switch off his life support and allow him to die peacefully.
His parents resisted, arguing an experimental treatment could extend and improve Charlie's life.
The case gained international attention after Charlie's parents received support from Pope Francis, U.S. President Donald Trump and some members of the U.S. Congress.
On Monday, the Vatican said Pope Francis was praying for Charlie and his parents and urged the faithful to join him in prayer so the baby's parents "may find God's consolation and love."
As the legal battle dragged on, U.S.-based pro-life activists had flown to London to support Charlie's parents, and the case became a flashpoint for opposing views on health-care funding, medical intervention, the role of the state and the rights of the child.
Passions often have run high, with activists demanding "justice for Charlie" rallying outside the High Court and Great Ormond Street Hospital. Over the weekend, the hospital said it had contacted police after staff received abuse and threats.
Charlie's parents condemned the abuse. On Monday, they thanked the hospital for the care it had given their child.
Some commentators portrayed the case as a clash between family and the state, and U.S. conservatives used it to criticize Britain's government-funded health care system -- though the case never was about money.
Judge Nicholas Francis criticized those "who know almost nothing about this case but who feel entitled to express opinions."
At its heart, the case pitted the right of parents to decide what's best for their children against the authorities' responsibility to uphold the rights of people who can't speak for themselves.
Under British law, children have rights independent of their parents, and it is usual for courts to intervene when parents and doctors disagree on the treatment of a child -- such as cases in which a parent's religious beliefs prohibit blood transfusions.
British courts and the European Court of Human Rights all ruled against Charlie's parents and in favor of Great Ormond Street. The case returned to court this month when the hospital asked the judge to reassess the possible benefits of a treatment pioneered by Dr. Michio Hirano, a neurology expert from Columbia Medical Center in New York.
At a hearing this month, Hirano said there was a 10 percent chance of improvement in Charlie's muscle use with the treatment, known as nucleoside therapy. But he conceded it never had been tried on a human with Charlie's condition; and no tests had been done on mice to see whether it would work on a patient like Charlie.
Hirano came to London last week to examine Charlie along with other experts. After seeing the results of new tests, the baby's parents agreed to drop their case, meaning Charlie's life support can now be removed.
But they still believe Charlie could have been saved had months not been spent in legal wrangling about whether he should get treatment.
"Had Charlie been given the treatment sooner he would have had the potential to be a normal, healthy little boy," Yates told the court.
"Our son has an extremely rare disease for which there is no accepted cure, but that does not mean that this treatment would not have worked, and it certainly does not mean that this shouldn't have been tried."
The hospital disagreed. Its lawyer, Katie Gollop, said Charlie had suffered "irreversible neurological damage" and the treatment would have been "futile." She said the hospital stood by its belief that Charlie was in pain.
"At the first hearing in Charlie's case in March, (Great Ormond Street Hospital's) position was that every day that passed was a day that was not in his best interests," Gollop said in a written statement. "That remains its view of his welfare."
The hospital also criticized Hirano, saying that he had given evidence to court without having read previous judgments or Charlie's medical records. And it noted that Hirano had told the court that he "retains a financial interest in some of the ... compounds he proposed prescribing for Charlie."
Ending a case he called tragic for all involved, the judge paid tribute to Charlie's parents, saying it was impossible to comprehend the agony they faced.
"No parent could have done more for their child," he said.
Yates cried as she told the court she and Charlie's father had only wanted the best for their son.
"We are so sorry that we couldn't save you," she said.
Connect with the Southeast Missourian Newsroom:
For corrections to this story or other insights for the editor, click here. To submit a letter to the editor, click here. To learn about the Southeast Missourian’s AI Policy, click here.